Details of the Drug

General Information of Drug (ID: DMI5UEB)

Drug Name

Unacylated ghrelin

Synonyms

AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D01TDY

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ghrelin (GHRL)	TT1OCL0	GHRL_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Alize Pharma announces positive results for AZP-531, its unacylated ghrelin analog, from two Phase I clinical trials in healthy volunteers and obese subjects. Lyon, France, December 10, 2014.
2	Alize Pharma signs research collaboration and license option agreement with Lilly. Lyon, France, January 25, 2010.